4SC AG Epigenetic Cancer Drugs Pipeline 2016

4SC AG is a Munich-based biopharmaceutical company developing epigenetic and immuno-oncology drugs for cancer treatment. The company's pipeline includes lead candidate resminostat in pivotal studies for cutaneous T-cell lymphoma and hepatocellular carcinoma, alongside Phase I/II programs in melanoma and gastrointestinal cancers.